Recent Developments in Global Cannabis Industry Resulting in Strains With Higher CBD Levels

Palm Beach, FL – (February 12, 2019) – Researchers in the UK have developed a new strain of cannabis that could help treat psychosis.  Recently, a British researcher, Dr. David Potter and his team, have turned their attention to developing a cannabis-based treatment for psychosis and related illnesses such as schizophrenia. “The most well-known ingredient in cannabis that gets people high is THC [or tetrahydrocannabinol],” says Potter, “But THC is just one of dozens of potentially useful cannabinoids in the plant.” Cannabinoids are chemicals that act on the brain’s cannabinoid receptors, part of a system that regulates a variety of physiological processes including pain sensation, mood, memory and appetite.  Purified CBD has been shown to have antipsychotic and anti-anxiety effects and can lessen the psychotic symptoms normally experienced by people given high doses of THC. Research by the University College London also suggests that people who smoke cannabis rich in CBD are less likely to experience “schizophrenia-like symptoms” than those who smoke cannabis containing only THC. The origins of modern cannabis can be traced to California in the late 1970s, when professional breeders began to select the most potent, THC-rich plants for the first time. In the quest to make ever stronger cannabis, illicit growers may have inadvertently bred out a chemical (CBD) that protected the mental health of users in the past.   Active companies in the markets this week include The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Aphria Inc. (NYSE: APHA) (TSX:APHA), The Supreme Cannabis Company, Inc. (TSX-V: FIRE) (OTC: SPRWF),  MedMen Enterprises Inc. (CSE: MMEN) (OTC: MMNFF), The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTC: TGODF).


Cannabis treatment is effective for chronic pain and nausea and vomiting due to chemotherapy, according to a 2017 report by the National Academies of Sciences, Engineering and Medicine.  Chronic pain is the most common reason given for medical marijuana prescriptions in the U.S., and chronic pain affects an estimated 100 million Americans, according to an article in  According to Statista, in 2018, legal sales of  cannabis amounted to nearly 10 billion U.S. dollars, and sales are projected to be over $16 billion in 2021, of which the State of Oregon is expected to account for almost $1 billion.


The Yield Growth Corp. (CSE:BOSS) (OTCPK:BOSQF) BREAKING NEWS:  Yield Growth Corp is pleased to announce that it has finalized product formulations and selected all THC and CBD strains for its first 9 products to launch in Oregon through a 400 retail distribution network.


Pursuant to its agreement with a licensed cannabis processing facility in Oregon, Yield Growth subsidiary UJ Topicals’ branded products will be launching in the Oregon legal cannabis market.   The products include CBD and THC oils, Analgesic Topical Gel with THC and CBD, Pain Balm with THC and CBD, Massage Oil with THC and CBD, and 3 types of capsules containing THC and Ayurvedic herbal formulations, blended with ingredients that have been used to treat arthritis and chronic pain.  All of the cannabis topical products have been formulated based on Urban Juve proprietary formulas, for which 11 provisional patents have been filed in the U.S.


“We have formulated our products with very high concentrations of THC and CBD for maximum effect,” says Penny Green, CEO of The Yield Growth Corp. “It’s our hope that Oregon residents will embrace our cannabis products as viable treatments for chronic pain.”    Read this and more news for The Yield Growth Corp. at:


Other recent developments and major influences in the healthcare/biotech industry include:


The Supreme Cannabis Company, Inc. (TSX-V: FIRE) (OTCQX: SPRWF) recently announced that  it has received approval from The Depository Trust Company (“DTC”) of New York to make the Company’s shares DTC eligible. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered to be “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors.  “DTC eligibility greatly simplifies the process of trading our common stock in the United States, further improving our investment appeal south of the border,” said Navdeep Dhaliwal, CEO of Supreme Cannabis.


Aphria Inc. (TSX: APHA) (NYSE: APHA) the company recently announced the appointment of Brett D. Marchand as Senior Vice President of Supply Chain effective February 11, 2019 . Previously, Mr. Marchand was Vice President of Supply Chain and Logistics Canada at The Northwest Company (“NWC”) where he was responsible for overseeing a supply network that supported 140 remote access retail grocery and general merchandise stores across Canada’s North.  “I am pleased to welcome Brett, a distinguished veteran and highly accomplished leader, into the Aphria family,” said Jakob Ripshtein, President of Aphria. “Brett’s tenure in similar roles across a broad scale of growth-focused companies has led to an impressive record of optimizing corporate operational strategies and maximizing profitability.


The Green Organic Dutchman Holdings Ltd. (TSX:TGOD.TO) (OTCQX: TGODF) the company recently announced that it had secured a cannabis supply agreement with the Ontario Cannabis Retail Corporation.   ” Ontario has the largest population in Canada and is a critical component to TGOD’s national recreational rollout,” commented Brian Athaide , Director and CEO. “This represents the first of many provincial supply agreements planned for our premium organic product as our domestic facilities near completion and production increases throughout 2019.”


MedMen Enterprises Inc. (CSE:MMEN.CN) (OTCQX: MMNFF) recently, the company announced that it has closed its previously announced acquisition (the “Acquisition”) of Seven Point, a licensed medical cannabis dispensary located in the historic Chicago suburb of Oak Park, Illinois.  Pursuant to the Acquisition, the Company paid a combination of cash at closing, deferred cash and subordinate voting shares of MedMen, for an undisclosed total amount.


DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates and, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty nine hundred dollars for news coverage of the current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: – +1(561)325-8757